Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2007
08/09/2007CA2637545A1 Anabaseine derivatives, pharmaceutical compositions and methods of use thereof
08/09/2007CA2637336A1 Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same
08/09/2007CA2637333A1 Tricyclic n-heteroaryl-carboxamide derivatives containing a benzimidazole unit, method for preparing same and their therapeutic use
08/09/2007CA2637316A1 A pharmaceutical composition comprising perindopril
08/09/2007CA2637255A1 40-o-(2-hydroxyethyl)-rapamycin for treating tuberous sclerosis disorders
08/09/2007CA2637172A1 Pyridin-2-amine derivatives and their use as glucokinase activators
08/09/2007CA2637083A1 Use of naphthyridine derivatives as medicaments
08/09/2007CA2637024A1 Substituted imidazole derivatives, compositions, and methods of use as ptpase inhibitors
08/09/2007CA2636981A1 7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
08/09/2007CA2636061A1 Flavor-enhancing compositions, methods of manufacture, and methods of use
08/09/2007CA2635814A1 Amido compounds and their use as pharmaceuticals
08/09/2007CA2635813A1 Urea derivatives as kinase inhibitors and methods of use thereof
08/09/2007CA2635800A1 Preventive/remedy for urinary calculosis
08/09/2007CA2635718A1 Methods of using hedgehog kinase antagonists to inhibit hedgehog signaling and to treat hedgehog mediated disorders
08/09/2007CA2635531A1 Multicyclic amino acid derivatives and methods of their use
08/09/2007CA2635403A1 Compounds for the inhibition of integrins and use thereof
08/09/2007CA2635272A1 Fast acting inhibitor of gastric acid secretion
08/09/2007CA2634879A1 Pharmaceutical formulations of oxcarbazepine and methods for its preparation
08/09/2007CA2634286A1 Compositions and methods for regulating complement system
08/09/2007CA2633568A1 Piperidine and piperazine derivatives
08/09/2007CA2630675A1 Transdermal therapeutic system for volatile and/or thermolabile substances
08/09/2007CA2630240A1 Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
08/09/2007CA2627682A1 Polycyclic 1, 2, 3, 4 -tetrahydro- isoquinoline derivatives and compositions comprising them as ppar modulators
08/09/2007CA2627644A1 Compounds and compositions as ppar modulators
08/09/2007CA2622679A1 Immunostimulatory single-stranded ribonucleic acid with phosphodiester backbone
08/09/2007CA2578433A1 Methods and compositions related to production of coenzyme q10
08/09/2007CA2577468A1 Composition and method for pre-surgical skin disinfection
08/08/2007EP1816194A1 Cancer-cell-specific proliferation inhibitors
08/08/2007EP1816191A1 METHOD OF SCREENING COMPOUND REGULATING THE TRANSLATION OF SPECIFIC mRNA
08/08/2007EP1816128A1 Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof
08/08/2007EP1816127A1 Triazine derivatives for use as selective npy (y5) antagonists
08/08/2007EP1816126A1 Process for preparation of rosuvastatin calcium
08/08/2007EP1816125A1 Novel crystalline forms of an antagonist of CB1 cannabinoid receptor and preparation method thereof
08/08/2007EP1816124A2 Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy
08/08/2007EP1816123A1 Intermediates for the production of pharmaceutically active compounds
08/08/2007EP1816122A2 3,4,5-substituted piperidines as therapeutic compounds
08/08/2007EP1816121A1 9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments
08/08/2007EP1815869A1 Method of changing morphology of block copolymer
08/08/2007EP1815867A1 Combination drug for treating autoimmune disease
08/08/2007EP1815866A1 Remedy or preventive for ischemic cardiac disease or ischemic cardiac myopathy
08/08/2007EP1815865A1 Therapeutic agent for diabetes comprising protease-inhibiting compound
08/08/2007EP1815861A2 Ionene polymers and their use as antimicrobial agents
08/08/2007EP1815860A2 Phosphate transport inhibitors
08/08/2007EP1815859A2 Halimide, a cytotoxic marine natural product, and derivatives thereof
08/08/2007EP1815858A2 Association between a peroxisome proliferator-activated receptor ligand and an antioxidant agent and the pharmaceutical compositions that contain them
08/08/2007EP1815857A1 A pharmaceutical composition comprising perindopril
08/08/2007EP1815856A2 A cancer vaccine
08/08/2007EP1815855A1 Pharmaceutical composition for modified release insulin sensitiser
08/08/2007EP1815854A1 Treatment of dyskenesia
08/08/2007EP1815853A1 Therapeutic agent for drug dependence
08/08/2007EP1815852A1 Nonaqueous preparation for percutaneous absorption containing nonsteroidal antiflammatory analgesic
08/08/2007EP1815850A1 Controlled release formulation of divalproic acid and its derivatives
08/08/2007EP1815849A1 Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
08/08/2007EP1815847A2 Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
08/08/2007EP1815846A2 Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
08/08/2007EP1815844A2 Photoprotecting compositions reducing the risk of skin sensitisation
08/08/2007EP1815247A2 Therapeutic use of farnesyltransferase inhibitors and methods of monitoring the efficacy thereof
08/08/2007EP1815022A2 Method of determining a cellular response to a biological agent
08/08/2007EP1815006A1 Inhibitors of biotin protein ligase
08/08/2007EP1814989A2 Methods and compositions for rna interference
08/08/2007EP1814907A2 Kit of parts designed for implementing an antitumoral or antiviral treatment in a mammal
08/08/2007EP1814895A2 Apparatus and system having dry control gene silencing compositions
08/08/2007EP1814888A1 Azabenzoxazoles for the treatment of cns disorders
08/08/2007EP1814887A1 Azabenzoxazoles for the treatment of cns disorders
08/08/2007EP1814885A2 Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them
08/08/2007EP1814884A1 Process for preparing novel crystalline forms of (2s)-1-[[(7r)-7-(3,4-dichlorophenyl)-4,7-dihydro-5-methylpyrazolo[1,5]pyrimidine-6-yl]carbonyl]-2-(4-fluorophenyl) pyrrolidine, novel stable forms produced therein and formulations
08/08/2007EP1814883A1 Bicyclic inhibitors or rho kinase
08/08/2007EP1814882A1 Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
08/08/2007EP1814880A1 Imidazo[1,2-a]pyridine compounds, compositions, uses and methods related thereto
08/08/2007EP1814879A1 Derivatives of 4,7-dioxobenzothiazole-2-carboxamides, preparation method thereof and therapeutic uses of same
08/08/2007EP1814878A1 Spiro-2, 4-pyrimidinediamine compounds and their uses
08/08/2007EP1814877A2 Diphenyl substituted alkanes as flap inhibitors
08/08/2007EP1814876A2 Heterocyclic dye compounds for in vivo imaging and diagnosis of alzheimer's disease
08/08/2007EP1814875A2 Improved inhibitors for the soluble epoxide hydrolase
08/08/2007EP1814873A2 5-sulfonyl-1-piperidinyl substituted indole derivatives as 5-ht6 receptor antagonists for the treatment of cns disorders
08/08/2007EP1814872A1 Substituted [(phenylethanoyl)amino] benzamides and the use thereof in the treatment of inflammatory and cardio-vascular diseases
08/08/2007EP1814871A2 Compounds that modulate ppary type receptors, and use thereof in cosmetic or pharmaceutical compositions
08/08/2007EP1814869A2 Substituted amino acids as protein tyrosine phosphatase inhibitors
08/08/2007EP1814867A2 Aryl pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimicrobial agents
08/08/2007EP1814866A2 Gonadotropin releasing hormone receptor antagonists
08/08/2007EP1814865A2 Benzimidazole acetic acids exhibiting crth2 receptor antagonism and uses thereof
08/08/2007EP1814864A1 Nitro indazole derivatives
08/08/2007EP1814863A1 Indazole sulphonamide derivatives
08/08/2007EP1814861A1 Substituted 5-oxo pyrazoles and [1,2,4]triazoles as antiviral agents
08/08/2007EP1814860A1 Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents
08/08/2007EP1814857A1 Isotopically marked quinoline derivatives as adenosin a3 receptor ligands
08/08/2007EP1814856A1 Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
08/08/2007EP1814854A1 Cationic ceramides, and analogs thereof, and their use for preventing or treating cancer
08/08/2007EP1814853A2 Hydroxybenzoate salts of metanicotine compounds
08/08/2007EP1814852A2 Hydroxybenzoate salts of metanicotine compounds
08/08/2007EP1814851A2 4-phenylsulfonamidopiperidines as calcium channel blockers
08/08/2007EP1814850A1 New histone deacetylases inhibitors
08/08/2007EP1814849A1 Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
08/08/2007EP1814848A1 2,3,4-substituted-cyclopentanones as therapeutic agents
08/08/2007EP1814846A1 11beta-hsd1 inhibitors
08/08/2007EP1814841A2 Ceramides and apoptosis-signaling ligand
08/08/2007EP1814839A2 Immunotherapeutic agent
08/08/2007EP1814608A2 Medical devices containing rapamycin analogs
08/08/2007EP1814597A2 Rnai modulation of the bcr-abl fusion gene and uses thereof
08/08/2007EP1814596A2 Antisense antiviral compounds and methods for treating filovirus infection
1 ... 3635 3636 3637 3638 3639 3640 3641 3642 3643 3644 3645 3646 3647 3648 3649 3650 3651 3652 3653 3654 3655 ... 7860